Clinicopathological evaluation of renal allograft treated with anti-CD25 monoclonal antibody

被引:7
|
作者
Okamoto, M [1 ]
Akioka, K
Higuchi, A
Kadotani, Y
Ushigome, H
Uryuhara, K
Kaihara, S
Yoshimura, N
机构
[1] Kyoto Prefectural Univ Med, Dept Organ Interact Res Med, Kamigyo Ku, Kyoto 6028566, Japan
[2] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Transplantat & Regenerat Surg, Kyoto 6028566, Japan
关键词
anti-CD25 monoclonal antibody; kidney transplantation; protocol biopsy;
D O I
10.1111/j.1399-0012.2005.00404.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Twenty-seven living-donor kidney recipients were treated with the antibody against CD25 as the induction immunosuppressive agent. They did not develop acute rejection within 1 month after transplantation, and mean serum creatinine level at 1 month was 1.0 +/- 0.4 mg/dL. There were no findings of acute rejection or drug-induced nephrotoxity in protocol biopsies at 1 month following transplantation. After 1 month had passed, acute rejection occurred in three cases. The pathological grade of acute rejection varied from borderline to grade III by Banff classification. The careful inspection is necessary to find out the occurrences of acute rejection more than 2 months after transplantation because immunological situation has been changing around this period.
引用
收藏
页码:49 / 53
页数:5
相关论文
共 50 条
  • [1] Effects of anti-CD25 monoclonal antibody on the corneal allograft rejection in a rat model
    Gong, Yu-Bo
    Lu, Xiao-He
    Zhou, Jin
    Yuan, Wei
    Huang, Yi-Fei
    AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, 2010, 4 (07): : 440 - 447
  • [2] Inhibition of the IL-15 pathway in anti-CD25 mAb treated renal allograft recipients
    Baan, CC
    van Riemsdijk-Overbeeke, IC
    Boelaars-van Haperen, MJAM
    IJzermans, JMN
    Weimar, W
    TRANSPLANT IMMUNOLOGY, 2002, 10 (01) : 81 - 87
  • [3] Immunosuppression for neural xenografts: a comparison of cyclosporin and anti-CD25 monoclonal antibody
    Honey, CR
    Shen, H
    JOURNAL OF NEUROSURGERY, 1999, 91 (01) : 109 - 113
  • [4] A novel therapeutic option in pemphigus vulgaris: humanized monoclonal anti-CD25 antibody
    Renkl, A
    Mockenhaupt, M
    Technau, K
    Herouy, Y
    Norgauer, J
    BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (06) : 1220 - 1222
  • [5] ANTI-CD3 - ANTI-CD25 (CD3,25) BISPECIFIC MONOCLONAL-ANTIBODY (BSMAB) - TARGETING OF ACTIVATED T-CELLS AND PROLONGATION OF SKIN ALLOGRAFT
    MACLEAN, JA
    AUCHINCLOSS, H
    SU, Z
    WONG, JT
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1993, 91 (01) : 215 - 215
  • [6] Synergistic effect of an anti-CD25 antibody on MVAp53 treated mice
    Gibson, G
    Daftarian, P
    Song, GY
    Diamond, DJ
    Ellenhorn, J
    ANNALS OF SURGICAL ONCOLOGY, 2005, 12 (02) : S42 - S42
  • [7] TARGETING OF SAPORIN TO CD25-POSITIVE NORMAL AND NEOPLASTIC LYMPHOCYTES BY AN ANTI-SAPORIN ANTI-CD25 BISPECIFIC MONOCLONAL-ANTIBODY - INVITRO EVALUATION
    TAZZARI, PL
    ZHANG, S
    CHEN, Q
    SFORZINI, S
    BOLOGNESI, A
    STIRPE, F
    XIE, H
    MORETTA, A
    FERRINI, S
    BRITISH JOURNAL OF CANCER, 1993, 67 (06) : 1248 - 1253
  • [8] Treatment of severe psoriasis with anti-CD25 monoclonal antibodies
    Mrowietz, U
    Zhu, KJ
    Christophers, E
    ARCHIVES OF DERMATOLOGY, 2000, 136 (05) : 675 - 676
  • [9] Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis
    Martin, Roland
    CLINICAL IMMUNOLOGY, 2012, 142 (01) : 9 - 14
  • [10] Suppression of Tumour Metastasis in a Murine Osteosarcoma Model with Anti-CD25 Monoclonal Antibody Treatment
    Kozawa, Eiji
    Sugiura, Hideshi
    Wasa, Junshi
    Kohyama, Keishi
    Yamada, Kenji
    Nishioka, Akiko
    Nishida, Yoshihiro
    Ishiguro, Naoki
    Taguchi, Osamu
    ANTICANCER RESEARCH, 2010, 30 (12) : 5019 - 5022